Drug Trial Radar · NCT01964378
CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer
Last checked: Nov 20, 2026Latest source record: Jul 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
200
Actual
Start
Oct 29, 2013
Primary completion
Oct 16, 2015
Study completion Oct 16, 2015
Sponsor
- Lead sponsor
- Tris Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 17, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pain is one of the most common symptoms associated with malignant tumor. The purpose of this trial is to determine whether cebranopadol is as effective in patients with cancer related pain as morphine sulfate prolonged release (PR).
Conditions
- Pain
- Neoplasms
- Chronic Pain
Interventions
CebranopadolDrug
Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.
Morphine Prolonged ReleaseDrug
Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average Amount of Daily Rescue Medication at the End of the Maintenance Period (Per Protocol Set)Time frame: The last 2 weeks of the expected 6-week treatment period.
- Average Amount of Daily Rescue Medication at the End of the Maintenance Period (Full Analysis Set)Time frame: The last 2 weeks of the expected 6-week treatment period.
Locations
42 sites in 14 countries. Site status is shown where the registry gives one.
AT004
Vienna, Austria
BE005
Brussels, Belgium
BE002
Ottignies, Belgium
BE001
Sint-Niklaas, Belgium
BG001
Shumen, Bulgaria
BG008
Sofia, Bulgaria
BG003
Sofia, Bulgaria
BG006
Sofia, Bulgaria
BG007
Sofia, Bulgaria
BG004
Varna, Bulgaria
BG005
Vratsa, Bulgaria
CL005
Temuco, Chile
HR001
Zagreb, Croatia
DK006
Aalborg, Denmark
DK004
Herlev, Denmark
DE008
Böhlen, Germany
DE010
München, Germany
HU004
Gyula, Hungary
HU002
Miskolc, Hungary
HU011
Nyíregyháza, Hungary
PL012
Będzin, Poland
PL008
Bydgoszcz, Poland
PL013
Chorzów, Poland
PL014
Dąbrowa Górnicza, Poland
PL003
Gdansk, Poland
PL010
Gliwice, Poland
PL015
Warsaw, Poland
PL002
Włocławek, Poland
RO001
Brasov, Romania
RO002
Cluj-Napoca, Romania
RO009
Constanța, Romania
RO011
Craiova, Romania
RS001
Belgrade, Serbia
RS003
Belgrade, Serbia
RS002
Kamenitz, Serbia
RS005
Zrenjanin, Serbia
SK007
Bratislava, Slovakia
SK004
Bratislava, Slovakia
SK001
Prešov, Slovakia
SK005
Pruské, Slovakia
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.